Meet Our Team

Matti Jalasvuori has conducted bacteriophage research at both the University of Cambridge and the Australian National University, before leading his own research group for over a decade at the University of Jyväskylä, Finland. In addition to his academic experience, he has authored science books to familiarise general audiences with phages and other viruses

Saija Kiljunen is a Principal Investigator of Phage Therapy Research group at the Department of Medicine, University of Helsinki. She has participated in several phage therapy cases and is involved in a variety of significant academic collaborations in the bacteriophage space.

Dr. Hoikkala brings a rare blend of computational expertise and biological insight to the team. With a broad experience in developing and optimizing bioinformatics tools, he excels at bridging the gap between biological science and software engineering.

Dr. Chisty brings more than 20 years of business experience and a strong scientific background from the University of Oxford, UK. Her past roles in several technology transfer offices across London have equipped her with in-depth knowledge of running successful spin-out companies.

With over three decades of experience in senior leadership positions across the public and private ICT sectors, Olli Porkholm has built a distinguished career with organizations such as Hewlett-Packard, Nokia, and Tieto. He has also served as CEO and Board Member of Protacon Solutions Oy. In recent years, his work has centered on board governance and investment activities.

Kaija Korpiaho-Haga is an accomplished entrepreneur with more than 20 years of experience in the pharmaceutical sector. She founded and successfully led a prominent pharmaceutical consultancy as CEO, guiding the company to a successful exit. In addition to her current executive roles in an investment company, as the owner of the Women’s Investment Club, and as a co-founder of a regulatory consultancy company, she serves on multiple boards and advisory boards, contributing her strategic insight, entrepreneurial mindset, and leadership expertise to diverse organizations.

Matti Hautsalo has been working for two decades in investing in early stage research empowered startups, both via VC and managing a private investment vehicle. He has held various operationally intensive board roles in companies combining a Nordic R&D team with international management and investor base. His investments and directorships range from computation intensive life sciences to drug development and health care, including cancer immunotherapy (Valo Tx), quantum chemistry (Algorithmiq), live cell analysis (CM Technologies), whole body MRI (Prenuvo), and health care ERP (Commit;).

Saija Kiljunen is a Principal Investigator of Phage Therapy Research group at the Department of Medicine, University of Helsinki. She has participated in several phage therapy cases and is involved in a variety of significant academic collaborations in the bacteriophage space.

Matti Jalasvuori has conducted bacteriophage research at both the University of Cambridge and the Australian National University, before leading his own research group for over a decade at the University of Jyväskylä, Finland. In addition to his academic experience, he has authored science books to familiarise general audiences with phages and other viruses